Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy

Head and Neck

Volumn 33, Issue 2, 2011, Pages 251-256

  Lau, Harold Y ^a   Brar, Sony ^b   Klimowicz, Alexander C ^a   Petrillo, Stephanie K ^a   Hao, Desirée ^a   Brockton, Nigel T ^c   Kong, Christina S ^d   Lees Miller, Susan P ^b   Magliocco, Anthony M ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ALBERTA HEALTH SERVICES   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemotherapy; head and neck cancer; HPV; p16; radiation

Indexed keywords

CISPLATIN; GENOMIC DNA; PROTEIN P16;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORIMETRY; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78751547579     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21439     Document Type: Article

References (26)

1. Brandsma JL, Steinberg BM, Abramson AL, Winkler B,. Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx. Cancer Res 1986; 46: 2185-2188.
2. Brandsma JL, Abramson AL,. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 1989; 115: 621-625.
3. Dahlstrand H, Nasman A, Romanitan M, Lindquist D, Ramqvist T, Dalianis T,. Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer. Anticancer Res 2008; 28: 1133-1138.
4. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
5. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636.
6. Dahlstrand H, Dahlgren L, Lindquist D, Munck-Wikland E, Dalianis T,. Presence of human papillomavirus in tonsillar cancer is a favourable prognostic factor for clinical outcome. Anticancer Res 2004; 24: 1829-1835.
7. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
8. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L,. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001; 23: 579-589.
9. Fu K,. Combined-modality therapy for head and neck cancer. Oncology 1997; 11: 1781-1796. (Pubitemid 28028467)
10. Hao D, Ritter MA, Oliver T, Browman GP,. Platinum-based concurrent chemoradiotherapy for tumors of the head and neck and the esophagus. Semin Radiat Oncol 2006; 16: 10-19.
11. Konig F, Krekeler G, Honig JF, Cordon-Cardo C, Fischer G, Korabiowska M,. Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas-a tissue microarray study. Anticancer Res 2007; 27: 283-288.
12. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-1738.
13. Wittekindt C, Gultekin E, Weissenborn SJ, Dienes HP, Pfister HJ, Klussmann JP,. Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol 2005; 62: 72-80.
14. Lau H, Brar S, Hao D, MacKinnon J, Yee D, Gluck S,. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: analysis of survival and toxicity. Head Neck 2006; 28: 189-196.
15. Kaplan EL, Meier P,. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE,. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554.
17. Pepe M,. Inference for events with dependent risks in multiple end-point studies. J Am Stat Assoc 1991; 86: 770-778.
18. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
19. Begum S, Gillison ML, Nicol TL, Westra WH,. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 1186-1191.
20. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74: 553-561.
21. Rischin D, Young R, Fisher R, et al. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. Proc 2009 ASCO Annual Meeting. 2009; 302s (abstract).
22. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221.
23. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
24. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
25. Gupta AK, Lee JH, Wilke WW, et al. Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys 2009; 74: 928-933.
26. Gillison ML,. HPV and prognosis for patients with oropharynx cancer. Eur J Cancer 2009; 45 (Suppl 1): 383-385.